Evolocumab had no effect in young women with familial hypercholesterolemia
Keywords:
familial hypercholesterolemia, Compound heterozygous, low density lipoprotein cholesterol, atherosclerosis, Xanthomatosis, PCSK9 inhibitors, evolocumabAbstract
Familial hypercholesterolemia is an autosomal dominant genetic disorder characterised by a significant increase of blood cholesterol level, premature development andprogression of atherosclerosis. In case of homozygous form total cholesterol, level exceeds 14 mmol/l. The article presents the case of absence of PCSK9 inhibitor effect in a young woman with familial hypercholesterolemia, compound heterozygous for the low density lipoprotein receptor gene, who needs therapy with PCSK9 inhibitors, according to the Russian guidelines on the diagnosis and treatment of familial hypercholesterolemia.
Downloads
Download data is not yet available.
Downloads
Published
2018-03-26
How to Cite
Benimetskaya K. S., Makarenkova K. V., Latyntseva L. D., Tsygankova O. V., Astrakov S. V., Shachtschneider E. V., Ragino Y. I., Voivode M. I. Evolocumab had no effect in young women with familial hypercholesterolemia // The Journal of Atherosclerosis and Dyslipidemias. 2018. VOL. № 1 (30). PP. 67–71.
Issue
Section
Clinical Case